Mucosal lichen planus: An evidence-based treatment update

Parastoo Davari, Hui Hua Hsiao, Nasim Fazel

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Mucosal lichen planus (MLP) is a chronic mucosal disorder that often poses a therapeutic challenge to dermatologists, dentists, and gynecologists. To relieve patients' pain and discomfort, improve their quality of life, and achieve clinical improvement, various therapeutic approaches can be considered for this disease. Based on the current literature it is difficult to define any particular treatment as the main therapeutic modality. Objective: We aimed to systematically review the current literature for the effectiveness of available treatment modalities for MLP. Methods: All of the randomized controlled trials and systematic reviews of MLP were collected by searching Pubmed, EMBASE, the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and China National Knowledge Infrastructure. Meta-analysis was performed, if possible. Results: Topical betamethasone valerate, clobetasol-17-propionate, and fluocinonide are effective in the treatment of oral lichen planus (OLP) when compared with placebo. Calcineurin inhibitors and topical retinoids are also beneficial treatment options. Limitations: The review does not include therapies with a lower level of evidence. Conclusion: Topical corticosteroids are the mainstay of therapy for OLP. High-quality evidence is lacking for the treatment of lichen planus.

Original languageEnglish (US)
Pages (from-to)181-195
Number of pages15
JournalAmerican Journal of Clinical Dermatology
Volume15
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Lichen Planus
Oral Lichen Planus
Therapeutics
Databases
Fluocinonide
Betamethasone Valerate
Clobetasol
Biomedical Technology Assessment
Retinoids
Dentists
PubMed
Meta-Analysis
China
Adrenal Cortex Hormones
Randomized Controlled Trials
Placebos
Quality of Life
Pain

ASJC Scopus subject areas

  • Dermatology

Cite this

Mucosal lichen planus : An evidence-based treatment update. / Davari, Parastoo; Hsiao, Hui Hua; Fazel, Nasim.

In: American Journal of Clinical Dermatology, Vol. 15, No. 3, 2014, p. 181-195.

Research output: Contribution to journalArticle

Davari, Parastoo ; Hsiao, Hui Hua ; Fazel, Nasim. / Mucosal lichen planus : An evidence-based treatment update. In: American Journal of Clinical Dermatology. 2014 ; Vol. 15, No. 3. pp. 181-195.
@article{c59fc8c9e2b44abebc1d550bebd77f61,
title = "Mucosal lichen planus: An evidence-based treatment update",
abstract = "Background: Mucosal lichen planus (MLP) is a chronic mucosal disorder that often poses a therapeutic challenge to dermatologists, dentists, and gynecologists. To relieve patients' pain and discomfort, improve their quality of life, and achieve clinical improvement, various therapeutic approaches can be considered for this disease. Based on the current literature it is difficult to define any particular treatment as the main therapeutic modality. Objective: We aimed to systematically review the current literature for the effectiveness of available treatment modalities for MLP. Methods: All of the randomized controlled trials and systematic reviews of MLP were collected by searching Pubmed, EMBASE, the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and China National Knowledge Infrastructure. Meta-analysis was performed, if possible. Results: Topical betamethasone valerate, clobetasol-17-propionate, and fluocinonide are effective in the treatment of oral lichen planus (OLP) when compared with placebo. Calcineurin inhibitors and topical retinoids are also beneficial treatment options. Limitations: The review does not include therapies with a lower level of evidence. Conclusion: Topical corticosteroids are the mainstay of therapy for OLP. High-quality evidence is lacking for the treatment of lichen planus.",
author = "Parastoo Davari and Hsiao, {Hui Hua} and Nasim Fazel",
year = "2014",
doi = "10.1007/s40257-014-0068-6",
language = "English (US)",
volume = "15",
pages = "181--195",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Mucosal lichen planus

T2 - An evidence-based treatment update

AU - Davari, Parastoo

AU - Hsiao, Hui Hua

AU - Fazel, Nasim

PY - 2014

Y1 - 2014

N2 - Background: Mucosal lichen planus (MLP) is a chronic mucosal disorder that often poses a therapeutic challenge to dermatologists, dentists, and gynecologists. To relieve patients' pain and discomfort, improve their quality of life, and achieve clinical improvement, various therapeutic approaches can be considered for this disease. Based on the current literature it is difficult to define any particular treatment as the main therapeutic modality. Objective: We aimed to systematically review the current literature for the effectiveness of available treatment modalities for MLP. Methods: All of the randomized controlled trials and systematic reviews of MLP were collected by searching Pubmed, EMBASE, the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and China National Knowledge Infrastructure. Meta-analysis was performed, if possible. Results: Topical betamethasone valerate, clobetasol-17-propionate, and fluocinonide are effective in the treatment of oral lichen planus (OLP) when compared with placebo. Calcineurin inhibitors and topical retinoids are also beneficial treatment options. Limitations: The review does not include therapies with a lower level of evidence. Conclusion: Topical corticosteroids are the mainstay of therapy for OLP. High-quality evidence is lacking for the treatment of lichen planus.

AB - Background: Mucosal lichen planus (MLP) is a chronic mucosal disorder that often poses a therapeutic challenge to dermatologists, dentists, and gynecologists. To relieve patients' pain and discomfort, improve their quality of life, and achieve clinical improvement, various therapeutic approaches can be considered for this disease. Based on the current literature it is difficult to define any particular treatment as the main therapeutic modality. Objective: We aimed to systematically review the current literature for the effectiveness of available treatment modalities for MLP. Methods: All of the randomized controlled trials and systematic reviews of MLP were collected by searching Pubmed, EMBASE, the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and China National Knowledge Infrastructure. Meta-analysis was performed, if possible. Results: Topical betamethasone valerate, clobetasol-17-propionate, and fluocinonide are effective in the treatment of oral lichen planus (OLP) when compared with placebo. Calcineurin inhibitors and topical retinoids are also beneficial treatment options. Limitations: The review does not include therapies with a lower level of evidence. Conclusion: Topical corticosteroids are the mainstay of therapy for OLP. High-quality evidence is lacking for the treatment of lichen planus.

UR - http://www.scopus.com/inward/record.url?scp=84904358685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904358685&partnerID=8YFLogxK

U2 - 10.1007/s40257-014-0068-6

DO - 10.1007/s40257-014-0068-6

M3 - Article

C2 - 24781705

AN - SCOPUS:84904358685

VL - 15

SP - 181

EP - 195

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 3

ER -